<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04074317</url>
  </required_header>
  <id_info>
    <org_study_id>DPI-201</org_study_id>
    <nct_id>NCT04074317</nct_id>
  </id_info>
  <brief_title>Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D</brief_title>
  <official_title>A Phase 2, Single-Dose, Randomized, Open-Label, Active-Controlled, Crossover, Pharmacodynamic, and Pharmacokinetic Comparative Study of a Novel Pramlintide-Insulin Co-Formulation in Adults With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xeris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xeris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, active-controlled, single-dose, 3-treatment, 3-period,
      3-way crossover, comparative PD and PK inpatient study in adults with T1D. The study
      comprises 5 visits: Screening (Visit 1), Treatment Periods (Visits 2 − 4), and Follow-Up
      (Visit 5).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2019</start_date>
  <completion_date type="Actual">April 2, 2020</completion_date>
  <primary_completion_date type="Actual">April 2, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve 0-180 minutes</measure>
    <time_frame>0-180 minutes following administration of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose time above 180 mg/dL</measure>
    <time_frame>0-180 minutes following administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose time in range</measure>
    <time_frame>0-180 minutes following administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose maximum concentration (Cmax)</measure>
    <time_frame>0-180 minutes following administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose time to maximum concentration (Tmax)</measure>
    <time_frame>0-180 minutes following administration of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Insulin-dependent Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>PRAM9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xeris pramlintide + insulin co-formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular Insulin + Pramlintide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Humulin® + Symlin® pen as separate injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Humulin®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRAM9</intervention_name>
    <description>SC injection</description>
    <arm_group_label>PRAM9</arm_group_label>
    <arm_group_label>Regular Insulin</arm_group_label>
    <arm_group_label>Regular Insulin + Pramlintide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular Insulin + Pramlintide</intervention_name>
    <description>Separate SC injections</description>
    <arm_group_label>PRAM9</arm_group_label>
    <arm_group_label>Regular Insulin</arm_group_label>
    <arm_group_label>Regular Insulin + Pramlintide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular Insulin</intervention_name>
    <description>SC injection</description>
    <arm_group_label>PRAM9</arm_group_label>
    <arm_group_label>Regular Insulin</arm_group_label>
    <arm_group_label>Regular Insulin + Pramlintide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Understands the study procedures, alternative treatment available, and risks involved
             with the study, and voluntarily agrees to participate by giving written informed
             consent

          2. Male or non-pregnant, non-lactating female diagnosed with T1D for at least 24 months
             prior to Screening.

          3. Aged 18 to 64 years of age, inclusive

          4. On a stable insulin regimen for 21 days prior to Screening (no greater than ± 20%
             variability in total daily dose)

          5. Have a plasma C-peptide level &lt; 0.6 ng/mL at Screening

          6. Have an HbA1c &lt; 10% at Screening

          7. Body mass index (BMI) in the range of ≥ 18 to ≤ 35 kg/m2 at Screening

          8. For women of childbearing potential, there is a requirement for a negative urine
             pregnancy test at Screening and for agreement to use contraception throughout the
             study and for 7 days after the last dose of study drug. Acceptable contraception
             includes birth control pill/patch/vaginal ring, Depo-Provera® (medroxyprogesterone
             acetate), Norplant® System (levonorgestrel), an intra-uterine device (IUD), the double
             barrier method (the woman uses a diaphragm and spermicide and the man uses a condom),
             or abstinence.

          9. Fasting Serum triglyceride concentration &lt; 200 mg/dL

        Exclusion Criteria:

          1. Currently being treated with pramlintide or has discontinued pramlintide within 21
             days of Screening

          2. Currently using an insulin pump

          3. Has renal insufficiency (serum creatinine &gt; 3.0 mg/dL) or end-stage renal disease
             requiring renal replacement therapy

          4. Has hepatic disease, including serum ALT or AST ≥ 3 times the upper limit of normal
             (ULN)

          5. Has hepatic synthetic insufficiency (serum albumin &lt; 3.0 g/dL) Has hematocrit ≤ 30%

          6. Has hematocrit ≤ 30%

          7. Has out-of-range systolic or diastolic BP readings at Screening (systolic BP &lt; 90 or &gt;
             150 mm Hg or diastolic BP &lt; 50 or &gt; 100 mm Hg)

          8. Has clinically significant ECG abnormalities at Screening

          9. Has congestive heart failure, NYHA Class III or IV

         10. Has history of myocardial infarction, unstable angina, or revascularization within 6
             months prior to Screening

         11. Has history of a cerebrovascular accident in 6 months prior to Screening with major
             neurological deficits

         12. Has active malignancy within 5 years prior to Screening (exception: basal cell or
             squamous cell skin cancers)

         13. Has had major surgical operation within 60 days prior to Screening or planned surgical
             operation during the study

         14. Has a seizure disorder (other than with suspected or documented hypoglycemia)

         15. Has a current bleeding disorder, treatment with anticoagulants, or platelet count &lt; 50
             ×109/L

         16. Has a history of allergies or significant hypersensitivity to pramlintide or any
             pramlintide-related products or to any of the excipients in the investigational
             formulation

         17. Has a history of positive test result for hepatitis B virus (HBV), hepatitis C virus
             (HCV), or human immunodeficiency virus (HIV)

         18. Has a concurrent illness not controlled by a stable therapeutic regimen

         19. Tests positive for drugs of abuse at Screening. Subjects testing positive for
             tetrahydrocannabinol (THC) at Screening or reporting active marijuana use will be
             allowed to participate in the study at the discretion of the investigator.

         20. Has active substance or alcohol abuse (&gt; 21 drinks/week for males or &gt; 14 drinks/week
             for females)

         21. Has participated in other studies involving administration of an investigational drug
             within 30 days or 5 half-lives prior to Screening (whichever is longer) or during
             participation in the current study

         22. There is any reason the investigator deems exclusionary

         23. Has donated blood within 8 weeks prior to Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Valasquez</last_name>
    <role>Study Director</role>
    <affiliation>Worldwide Clinical Trials</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Atiee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Worldwide Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>World Wide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Pramlintide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

